Flagship Harbor Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Flagship Harbor Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60	Closed	-$3.57K	–	899
2025 Q4	$3.57K	Buy	+60	New	+$3.27K	﹤0.01%	1724
2020 Q4	–	Sell	-109	Closed	-$8K	–	682
2020 Q3	$8K	Buy	109 +17	+18%	+$1.72K	﹤0.01%	1385
2020 Q2	$11K	Buy	+92	New	+$9.14K	﹤0.01%	1316
2018 Q4	–	Sell	-254	Closed	-$25K	–	1855
2018 Q3	$25K	Hold	254	–	–	﹤0.01%	1042
2018 Q2	$23K	Buy	+254	New	+$22.2K	﹤0.01%	1045

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Flagship Harbor Advisors's BMRN Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 60 shares — an estimated $3.57K sold.

Flagship Harbor Advisors first reported a position in BMRN in Q2 2018 and held it in 5 quarters. The position peaked at $25K in Q3 2018. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Flagship Harbor Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 60 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $3.57K.
Flagship Harbor Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Flagship Harbor Advisors's BioMarin Pharmaceuticals position peaked at $25K in Q3 2018.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.